Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 26724

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Biotechnology
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.

IPSCIO Record ID: 7362

License Grant
Pursuant to the Agreement, the Licensee has an option to acquire an exclusive, worldwide (excluding Japan) License of our Tcelna program for the treatment of MS.
License Property
The Licensor is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS). This therapy is based on proprietary T-cell technology. MS is a chronic, often disabling disease that affects the central nervous system. MS attacks the covering surrounding nerve cells, or myelin sheaths, leading to loss of myelin (demyelination) and nerve damage.

Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with SPMS. It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathTM, our proprietary methodd for the production of a patient-specific T-cell immunotherapy which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of MRTCs raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient.

IPSCIO Record ID: 26495

License Grant
The contract provides for worldwide distribution rights with a privately held British company for so long as there are patents and there is a continued corporate existence of the parties.
License Property
NEBO 178 is a development stage process using stem cell technology to develop biological compounds for the intended treatment of Alzheimers Disease and related neurological disorders.  The treatment process relies upon basic stem cell research to develop anticipated biological products for treatment of this disease or related neurological disorders.  The product is being developed in a joint development and marketing agreement with a privately held British corporation.
Field of Use
The rights granted relate to neurological disorders, i.e. Alzheimers.

IPSCIO Record ID: 240497

License Grant
Under the terms of the collaboration agreement with Licensee, the Licensor will receive a tiered royalty for the sale of OCREVUS.
License Property
OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies.

Primary Progressive Multiple Sclerosis, MS (PPMS) is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26620

License Grant
The Licensee has an exclusive, worldwide license from the College to develop and commercialize three technology areas for MS, namely T-cell vaccination, peptides, and diagnostics. Under the License Agreement with the College, the licensee will have rights to a total of 7 patents (2 U.S. and 5 foreign) and 69 patent applications (6 U.S., 62 foreign, and 1 Patent Cooperation Treaty [PCT]). Our multiple sclerosis cell therapy, Tovaxin, is currently in Phase I/II studies.
License Property
Tovaxin consists of modified auto reactive T cells. Multiple sclerosis is a result of a person’s own T cells attacking the myelin sheath that coats the nerve cells of the central nervous system. These T cells, that attack a person’s own body, are referred to as auto reactive T cells. In our treatment the T cells are taken from the patient, modified and returned to the patient. The modified T cells cause an immune response directed at the auto reactive T cells in the patient’s body. This immune response reduces the level of auto reactive T cells and potentially allows the myelin sheath to be repaired. In addition, we are evaluating whether this technology will allow us to diagnose multiple sclerosis and determine the severity of the disease through an analysis of the level of auto reactive T cells in a patient’s blood.

IPSCIO Record ID: 797

License Grant
The Licensor grants the Licensee exclusive, nontransferable Licenses for: the Applications and the Patents; and the Trademarks, until the Patents expire.

The grant of each License hereunder includes the right to grant subLicenses to Related Companies.

License Property
Applications means PCT/US2009/062895, entitled Medication and Treatment for Disease.

Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.

Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure).[1] Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.

Field of Use
Trial usage of Feldetrex â„¢ has been used in patients with Multiple Sclerosis.

Licensee shall prominently use the Trademark on Licensed Products.

IPSCIO Record ID: 26622

License Grant
The Licensor hereby grants to the Company an exclusive, including to the exclusion of REVIMMUNE, perpetual subLicense to the SubLicensed Rights throughout the territory, with the right to grant further subLicenses, to develop, promote, market, sell, make, have made, use, import, offer for sale, and commercialize the SubLicensed Products for the SubLicense Indications in the territory. Revimmune is a patent-pending pharmaceutical treatment in late-stage development for a variety of autoimmune diseases.
License Property
Revimmune uses an ultra-high intensity, short-course of an intravenous formulation of an approved drug (cyclophosphamide), in a new patent-pending method to reboot a patient’s immune system, thereby eliminating the autoimmunity, whereas current therapies including oral cyclophosphamide are used chronically to try to suppress the inflammation of autoimmunity. Based on long-term follow-up showing complete remissions, there is substantial evidence that Revimmune has the potential to cure cases of severe refractory autoimmune diseases such as aplastic anemia and myasthenia gravis. The Company's lead indication for Revimmune is multiple sclerosis (MS).

IPSCIO Record ID: 29372

License Grant
Through a purchase Agreement, the Company acquired rights related to certain treatment for scleroderma. The Company is obligated to pay a royalty on our net revenue from sales of Actimmune for the treatment of scleroderma.
License Property
Scleroderma is an autoimmune disease of the connective tissue. Autoimmune diseases are illnesses which occur when the body's tissues are attacked by its own immune system.

Actimmune® (interferon gamma-1b) is a bio-engineered interferon gamma, a naturally occurring human protein that acts as a biologic response modifier that stimulates the immune system and has direct effect on various cells in the body.

IPSCIO Record ID: 26493

License Grant
The Licensor a privately held British company and the Licensee have entered into an agreement which provides for the joint development and marketing of this product on a worldwide basis as long as the patent rights exist and the parties to the agreement continue.
License Property
NEBO 176 is a biological process based upon stem cell research to develop naturally occurring biological compounds for the treatment of Parkinsons Disease and related neurological disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.